Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.

Authors

Christoph Wanner
John M Lachin, George Washington University
Silvio E Inzucchi
David Fitchett
Michaela Mattheus
Jyothis George
Hans J Woerle
Uli C Broedl
Maximilian von Eynatten
Bernard Zinman

Document Type

Journal Article

Publication Date

1-9-2018

Journal

Circulation

Volume

137

Issue

2

Inclusive Pages

119-129

DOI

10.1161/CIRCULATIONAHA.117.028268

Keywords

Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Hospitalization; Humans; Kidney; Male; Middle Aged; Prevalence; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome

APA Citation

Wanner, C., Lachin, J., Inzucchi, S., Fitchett, D., Mattheus, M., George, J., Woerle, H., Broedl, U., von Eynatten, M., & Zinman, B. (2018). Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.. Circulation, 137 (2). http://dx.doi.org/10.1161/CIRCULATIONAHA.117.028268

Peer Reviewed

1